Evidence map›Paper›PMID 35547125›Full record

ArticleFrontiers in microbiology2022

Exploring the Therapeutic Potentials of Exopolysaccharides Derived From Lactic Acid Bacteria and Bifidobacteria: Antioxidant, Antitumor, and Periodontal Regeneration.

Maha A Khalil, Fatma I Sonbol, Lamiaa A Al-Madboly, Tamer A Aboshady, Abeer S Alqurashi, Sameh S Ali

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Draft genome sequence ofMicrobiology resource announcements · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Characterization and antioxidant activities of exopolysaccharides produced by Lactiplantibacillus plantarum strains isolated from Algerian fruits.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  9. Glucan exopolysaccharide fromFrontiers in molecular biosciences · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Maha A KhalilBiology Department, College of Science, Taif University, Taif, Saudi Arabia.
Fatma I SonbolPharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Lamiaa A Al-MadbolyPharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Tamer A AboshadyPeriodontology, Oral Medicine, Diagnosis and Radiology Department, Faculty of Dentistry, Tanta University, Tanta, Egypt.
Abeer S AlqurashiBiology Department, College of Science, Taif University, Taif, Saudi Arabia.
Sameh S AliBotany and Microbiology Department, Faculty of Science, Tanta University, Tanta, Egypt.
Tanta University · EGTaif University · SAJiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The metabolites of lactic acid bacteria (LAB) and bifidobacteria (Bb) have recently received a lot of attention due to their ability to protect interactions in blood and tissues, as well as their biodegradability and biocompatibility in human tissue. Exopolysaccharides (EPS) derived from bacteria have a long history of use in therapeutic and other industrial applications with no adverse effects. In this regard, EPSs were isolated and characterized from LAB and Bb culture supernatants to determine their antioxidant, antitumor, and periodontal regeneration properties. The antioxidant capacity of the EPSs varied with concentration (0.625-20 mg/ml). The highest antioxidant activity was found in LAB:

Indexed as

bifidobacteriaCaCo2exopolysaccharideHepG2lactic acid bacteriaMCF7RT-PCRtherapeutic agent

Identifiers

PMID35547125
PMCPMC9082500
OpenAlexW4285740543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.